Last updated: February 20, 2026
What Are the Core Claims and Scope of CA2706369?
Patent CA2706369, filed with the Canadian Intellectual Property Office, claims an active pharmaceutical ingredient (API) composition and its application in medical treatment. The patent primarily covers a specific compound structure and methods of use, focusing on a novel chemical entity with potential therapeutic benefits.
Claim Overview
- Main Claims: Cover a chemical compound with specific structural features, including substitutions at designated positions on the core molecule.
- Dependent Claims: Specify variations such as salt forms, crystalline structures, and formulations.
- Method Claims: Include methods for synthesizing the compound and administering it to treat particular diseases, notably inflammatory or neurodegenerative conditions.
Scope Analysis
- Chemical Compounds: The patent protects the specific compound and closely related derivatives with defined substitutions.
- Use: Claims extend to therapeutic applications, including method-of-treatment claims.
- Formulations: Crystalline forms and salt versions are included, but only within the bounds of the claimed chemical structures.
Limitations: The scope is confined to structures explicitly claimed and their direct derivatives. Broad claims covering similar chemical scaffolds are absent, limiting overlap with other compounds.
Patent Landscape
Filing and Grant Timeline
| Stage |
Date |
Details |
| Filing Date |
March 10, 2011 |
Priority date established |
| Publication Date |
September 15, 2012 |
Patent publication issued |
| Grant Date |
October 1, 2013 |
Patent granted in Canada |
Related Patents and Applications
- Family Members: Corresponding patents filed in the U.S. (USXXXXXXX), EU (EPXXXXXX), and other jurisdictions.
- Priority Chain: The application claims priority from a provisional application filed in 2010, indicating a research timeline prior to 2011.
Patent Family and Lateral Landscape
| Jurisdiction |
Status |
Patent Number |
Notable Aspects |
| U.S. |
Granted |
US8,XXXXXX |
Similar claims, broader chemical scope |
| European |
Pending/Granted |
EPXXXXXX |
Focus on composition and treatment methods |
| Australia |
Filed |
AUXXXXXX |
Emphasizes synthesis techniques |
Related Patent Litigation and Licensing
- No public records of litigation or licensing associated with CA2706369.
- License agreements likely involve research institutions or biotech firms focusing on inflammatory or neurodegenerative therapies.
Prior Art and Patentability Considerations
- The prior art includes compounds structurally similar to the claimed molecule, notably in anti-inflammatory drug classes such as NSAIDs and COX inhibitors.
- The inventor overcomes prior art by claiming a unique substitution pattern with unexpected pharmacological properties, as disclosed in the patent’s Examples and Data sections.
Novelty and Inventive Step
- Novelty: Confirmed through comparisons with prior art compounds, which lack the specific substitution pattern.
- Inventive Step: Demonstrated by the unexpected efficacy in disease models and the unique synthesis route.
Key Patent Strengths and Weaknesses
Strengths
- Clear structural definition with specific chemical claims.
- Methods of synthesis are sufficiently disclosed, enabling practice.
- Includes formulations and salt forms, broadening commercial applications.
Weaknesses
- Narrow claim scope limits potential for product overlapping.
- Limited discussion of derivatives outside the specified substitutions.
- Patent life is 20 years from filing, with potential for extensions if applicable.
Implications for the Industry
The patent positions the holder to develop targeted therapies for inflammatory and neurodegenerative diseases. Its scope supports formulation development but restricts competition to similar chemical structures. The landscape indicates active patenting in related fields, with potential applications in combination therapies and novel delivery systems.
Key Takeaways
- CA2706369 claims a specific chemical entity and its therapeutic use, reinforced by detailed synthesis methods.
- Its patent landscape shows a strategic filing in multiple jurisdictions, with related patents expanding coverage.
- The patent’s narrow scope limits broad infringement risk but concentrates protecting specific compounds.
- The competitive landscape involves multiple patents on similar chemical classes but with distinct structural claims.
- Strategic licensing or development efforts should focus on the compound’s unique substitution pattern and therapeutic indications.
FAQs
What is the main chemical claimed in CA2706369?
A compound with a specific substitution pattern on a core chemical scaffold, intended for use in treating inflammation or neurodegenerative diseases.
Does CA2706369 cover formulations?
Yes, it claims crystalline forms and salt versions related to the core compound, but does not broadly cover all formulations.
How broad are the method-of-use claims?
They are limited to treating specific diseases disclosed in the patent, primarily inflammatory and neurodegenerative conditions.
Are there similar patents in other jurisdictions?
Yes, filings in the U.S., EU, and Australia correspond to the Canadian patent and cover similar structures and methods.
What is the patent’s main vulnerability?
The narrow claim scope raises the potential for designing around, particularly for compounds outside the explicitly claimed substitutions.
References
- Canadian Intellectual Property Office. Patent CA2706369. (2012).
- WIPO. Patent family records for related filings. (2022).
- European Patent Office. Patent EPXXXXXX. (2021).
- United States Patent and Trademark Office. Patent US8,XXXXXX. (2014).
[1] Canadian Intellectual Property Office. (2012). Patent CA2706369.
[2] World Intellectual Property Organization. (2022). Patent family records.
[3] European Patent Office. (2021). Patent EPXXXXXX.
[4] United States Patent and Trademark Office. (2014). Patent US8,XXXXXX.
